We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pfizer Announces Positive Top-Line Data of Phase 3 Global Maternal Immunization Trial for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate.
- Authors
Saleem, Saba
- Abstract
The article reports that Pfizer Inc. announced positive top-line data from the Phase 3 clinical trial MATISSE (Maternal Immunization Study for Safety and Efficacy) investigating its bivalent RSV prefusion vaccine candidate, RSVpreF or PF-06928316 when administered to pregnant participants to help protect their infants from RSV disease after birth.
- Subjects
RESPIRATORY disease prevention; RESPIRATORY syncytial virus; MOTHERS; DRUG efficacy; DRUG approval; IMMUNIZATION; CLINICAL trials; VIRAL vaccines; INVESTIGATIONAL drugs; PHARMACEUTICAL industry; PATIENT safety; CHILDREN
- Publication
Neonatology Today, 2022, Vol 17, Issue 11, p131
- ISSN
1932-7129
- Publication type
Article